Moderna announced a global agreement under which Lonza Group will ramp up output of the proposed vaccine, which is based on a novel technology that relies on genetic material called mRNA.
They expect the first batches to be produced in the US in July Moderna Inc., one of the leaders among US companies developing experimental vaccines against the coronavirus, entered a pact with Lonza Group AG aimed at manufacturing 1 billion doses a year.
The companies announced a global agreement under which the Swiss chemical and pharmaceutical company will ramp up output of the proposed vaccine, which is based on a novel technology that relies on genetic material called mRNA.